Brief: FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027
21/09/2026 13:23
BRIEF-FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 Sept 21 (Reuters) - Insmed Incorporated INSM.O:
FDA GRANTS PRIORITY REVIEW TO INSMED'S SNDA FOR ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) FOR TREATMENT OF MAC LUNG DISEASE WITH PDUFA TARGET ACTION DATE SET FOR JANUARY 28, 2027
Source text: ID:nPn9bhGTPa
Further company coverage: INSM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector